Funding round-up: Dualyx, NewBiologix, Capitainer, DiogenX

France: DiogenX, a regenerative medicine biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has completed a €27.5m (US$30m) Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF). In this round, BIVF was joined by new investors Roche Venture Fund, Eli Lilly and Omnes, and historic investors JDRF T1D…

You must be a HMI Subscriber to view this content.

Subscribe Now »